By Sangeeta Chakraborty, Ph.D. O n October 27th, Exact Sciences announced its plan to add Thrive’s CancerSEEK to its growing array of early cancer diagnostics through a buyout of the privately held Thrive Earlier Detection Corp., in a stock and cash deal worth $2.15 billion. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. . Exact Sciences … The deal is expected to close in the first quarter of 2021. May 30, 2021 JHU Spinout Thrive Earlier Detection Lands up to $2.15 Billion in Acquisition by Exact Sciences Exact Sciences also Announces Acquisition of Base Genomics to Advance its With the support of our ongoing partnership with Johns Hopkins Exact Sciences is already home to two of the strongest and The acquisition of Thrive for up to $2.17 billion and Base Genomics for $410 million advances Exact Sciences’ efforts to be a leader in blood-based cancer screening. Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). “The acquisition of Thrive is a giant leap toward ensuring blood-based, multi-cancer screening becomes a reality and eventually, the standard of care,” said Exact Sciences chairman and CEO Kevin Conroy. Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a leader in the cancer-screening … Shares of blood-screening company Exact Sciences surge after it agrees to buy privately held cancer-detection provider Thrive Earlier Detection for $2.5 billion. Thrive Earlier Detection published data from DETECT-A, the first ever prospective, interventional study to use a blood test to screen for multiple types of cancers in a … Soon after the announcement, the stock price of Exact Sciences sky-rocketed to $134.33/per share on Tuesday … Thrive Earlier Detection was acquired by Exact Sciences on October 27, 2020 Life Science Company Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020 . Earlier this week, Exact Sciences agreed to buy Thrive, one of Grail’s competitors developing a cancer-detecting liquid biopsy sector, for $2.15 billion. Exact Sciences acquired Thrive in November for $2.1 billion. At Thrive, an Exact Sciences Company, our goal is to transform this outlook: to catch cancer earlier, including several with no screening options today, to improve patient outcomes. A cancer diagnosis is something no one wants to hear. Private Company. The deal will likely close in the first quarter of 2021. MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock … The cash and stock deal could be worth up to $2.15 billion, with $1.7 billion paid at an expected closing in the first quarter of 2021, and additional payments of $450 million if milestones related to the product are met. Exact Sciences Completes Acquisition Of Thrive Earlier Detection, Creating A Leader In Blood-Based, Multi-Cancer Screening. This is Exact Sciences’ 5th transaction in the United States. Exact Sciences Corp. today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. (“Thrive”). This is Exact Sciences’ 4th transaction in the Life Science sector. Thrive Earlier Detection has raised a total of $367M in funding over 2 rounds. No Comments. EXACT SCIENCES ALSO ACQUIRES Q1 ’21 POSITIONING EXACT SCIENCES AT THE FOREFRONT OF AN INCREDIBLE OPPORTUNITY TO SERVE PATIENTS AND IMPACT LIVES TOTAL ADDRESSABLE MARKET Cologuard $1B $.5B $25B Oncotype Multi-Cancer ABOUT Thrive is dedicated to incorporating earlier cancer detection into routine medical care, and Earlier this week, Exact Sciences agreed to buy Thrive, one of Grail’s competitors developing a cancer-detecting liquid biopsy sector, for $2.15 billion. Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. Less than two and a half years after it came out of stealth mode, the pan-cancer liquid biopsy developer Thrive Earlier Detection has been snapped up by Exact Sciences for $1.7bn up front. The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval. EXACT Sciences and Thrive Earlier Detection announced today that they have entered an agreement under which Exact Sciences will acquire Thrive. Exact Sciences (NSDQ:EXAS) announced today that it is acquiring cancer detection tech developer Thrive Earlier Detection for $2.15 billion.. EXACT Sciences and Thrive Earlier Detection announced today that they have entered an agreement under which Exact Sciences will acquire Thrive. Exact, which made its name with the Cologuard faecal test for colon cancer, has been developing a blood test capable of screening for a wide range of solid tumours, and data on this project released … By Meg Bryant. Exact Sciences Corp said on Tuesday it would buy cancer-screening firm Thrive Earlier Detection Corp in a cash-and-stock deal that could be valued up to $2.15 billion. These start-ups are racing to help doctors detect cancer early with a simple blood test Published Sat, Feb 1 2020 10:41 AM EST Updated Mon, Feb 3 2020 12:26 PM EST Christina Farr Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. The Life Sciences team advised Thrive Earlier Detection Corp. on its definitive agreement under which Exact Sciences Corp. (Nasdaq: EXAS) will acquire Thrive for cash and stock consideration of up to $2.15 billion.. Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. IndustryPRwire -- - Exact Sciences Corp announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. "Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care," said Kevin Conroy, chairman and CEO of Exact Sciences . Oct. 27, 2020. Thrive Earlier Detection Corp., a Baltimore, MD- and Cambridge, Mass.-based company dedicated to incorporating earlier cancer detection into routine medical care, raised $110m in Series A financing. Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. Exact also said that it has acquired DNA methylation analysis company Base Genomics for $410 million. “Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care,” said Kevin Conroy, chairman and CEO of the company. MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock … "Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care," said Kevin Conroy, chairman and CEO of Exact Sciences. Thrive is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). Thrive Earlier Detection is funded by 21 investors. JHU Spinout Thrive Earlier Detection Lands up to $2.15 Billion in. Today, it is often detected late, once it has spread and treatment options are often limited. Exact Sciences acquires Boston's Thrive Earlier Detection Corp. in $2.15B deal By Nick Williams – Reporter, Milwaukee Business Journal Author: M. Corey Goldman Under the terms of the agreement, Exact Science will pay $1.7 billion at closing, consisting of Exact Sciences common stock and 35% in cash. MADISON, Wis. and CAMBRIDGE, Mass. Exact Sciences acquired Thrive for up to $2.15B in 2021. Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives Photo courtesy of Exact Sciences. Thrive Earlier Detection, which launched just over a year ago with $110m in series A financing, is developing the CancerSEEK liquid biopsy, a technology licensed in from Bert Vogelstein’s lab at Johns Hopkins University. Exact Sciences to Acquire Thrive in Deal Valued at $2.15 Billion. In the larger acquisition, Exact Sciences said it agreed to acquire blood-based diagnostics developer Thrive Earlier Detection for up to … Their latest funding was raised on Jul 29, 2020 from a Series B round. Thrive Earlier Detection Corp’s backers include Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group and Exact Sciences… Rounding out the trifecta of cancer-focused liquid biopsy developers in the 2020 venture pool is Thrive Earlier Detection. Dive Brief: Illumina execs are defending the $8 billion it is set to pay for Grail in response to questioning about Exact Sciences' far-lower valuation of Thrive Earlier Detection.. MADISON, Wis., Jan. 5, 2021 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. (“Thrive”). MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection, a molecular diagnostics company founded by Vogelstein lab trainees from Johns Hopkins, for cash and stock consideration of up to $2.15 billion. Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. Exact Sciences, a US molecular diagnostics company, has agreed to acquire Thrive Earlier Detection in a cash cum stock deal worth up to $2.15 billion, in a move to become a leading player in blood-based, multi-cancer screening.. Based in Cambridge and Baltimore, Thrive Earlier Detection is a healthcare company focused on incorporating earlier cancer detection into routine … GuruFocus Article or News written by PRNewswire and the topic is about: In the larger acquisition, Exact Sciences said it agreed to acquire blood-based diagnostics developer Thrive Earlier Detection for up to … Thrive Earlier Detection published data from DETECT-A, the first ever prospective, interventional study to use a blood test to screen for multiple types of cancers in a … MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock … NEW YORK – Concurrent with the release of its third quarter earnings on Tuesday, Exact Sciences announced that it has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion, and that it has acquired DNA methylation analysis company Base Genomics for $410 million. The SaferSeqS technology has been licensed by Exact Sciences through Thrive Earlier Detection, the latter formed in 2019 with $110 million in Series A funding, the largest investment ever for a Johns Hopkins-licensed technology. Thrive Earlier … Press release content from PR Newswire. Under the agreement, Thrive … Kevin Conroy, Exact Sciences Corp. chairman and chief executive officer, discusses the company's purchase of cancer-screening provider Thrive Earlier Detection … Exact Sciences said Tuesday it plans to buy fellow liquid biopsy developer Thrive Earlier Detection in a cash-and-stock deal worth up to $2.15 billion, sending its stock up 19%. NEW YORK – Exact Sciences said on Tuesday morning that it has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion. From earlier cancer detection to treatment guidance and monitoring, Exact Sciences is helping people face their most challenging decisions with confidence. GuruFocus Article or News written by PRNewswire and the topic is about: . Read the Press Release. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support January 5, 2020. The AP news staff was not involved in its creation. Exact Sciences said today it has agreed to a pair of acquisitions designed to create a diagnostics powerhouse across multiple cancers. Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. Under the terms of the agreement, Cambridge, Mass.-based Thrive Earlier Detection will receive $1.7 billion up front - 65% in Exact Sciences common … Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer … EXACT SCIENCES ALSO ACQUIRES Q1 ’21 POSITIONING EXACT SCIENCES AT THE FOREFRONT OF AN INCREDIBLE OPPORTUNITY TO SERVE PATIENTS AND IMPACT LIVES TOTAL ADDRESSABLE MARKET Cologuard $1B $.5B $25B Oncotype Multi-Cancer ABOUT Thrive is dedicated to incorporating earlier cancer detection into routine medical care, and Exact Sciences to pay $2.56B for Thrive Earlier Detection, U.K. startup Base Genomics. BlueCross BlueShield Venture Partners and Exact Sciences are the most recent investors. Exact Sciences (NASDAQ:EXAS) has completed its acquisition of Thrive Earlier Detection Corp. "Bringing Thrive into the Exact Sciences family marks a … Exact Sciences Corp. EXAS, -2.65% said Tuesday it has agreed to acquire Thrive Earlier Detection Corp. in a cash and stock deal worth up to $2.15 billion. 1 Min Read. The cancer screening market is estimated to be worth over $25 billion. Thrive Earlier Detection envisions a future in which blood drawn at an annual physical is used to find early-stage cancer. Exact Sciences said today it has agreed to a pair of acquisitions designed to create a diagnostics powerhouse across multiple cancers. Exact Sciences also said that it had agreed to sell 8.6 million shares of stock at $101 a … Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening. E xact Sciences announced Tuesday it had acquired Thrive Earlier Detection, a liquid biopsy company that launched last year with technology … (Reuters) - Exact Sciences Corp EXAS.O said on Tuesday it would buy cancer-screening firm Thrive Earlier Detection Corp in a … Thrive's main offering is a not-yet-marketed blood-based test that screens for 10 cancers. EXACT Sciences and Thrive Earlier Detection announced today that they have entered an agreement under which Exact Sciences will acquire Thrive. Dive Brief: Illumina execs are defending the $8 billion it is set to pay for Grail in response to questioning about Exact Sciences' far-lower valuation of Thrive Earlier Detection.. In addition, Eli Casdin currently serves on the board of directors of Exact Sciences, a leader in the field of molecular screening for cancer. On October 27, 2020, Exact Sciences Corp. acquired life science company Thrive Earlier Detection Corp. for 2.2B USD Acquisition Highlights. In February 2009, Exact Sciences’ board of directors began searching for a new team to develop a non-invasive colorectal cancer screening test. Thrive Earlier is known as a health care company that provides cancer detection solutions. Madison-based Exact Sciences Corp. on Tuesday announced that it has completed its acquisition of cancer-screening firm Thrive Earlier Detection Corp. that was one of two deals announced Oct. 27. Investing.com -- Exact Sciences (NASDAQ: EXAS) jumped 18% after saying it will buy Thrive Earlier Detection Corp. for $2.15 billion, and announced a jump … Thrive Earlier Detection, a company that spun out of Johns Hopkins to commercialize a blood test for cancer, is set to be acquired by molecular diagnostics company Exact Sciences.